Regenera receives ethics approval for second clinical trial
Wednesday, 20 October, 2004
Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.
Visagen is a preservative free formulation of the steroid triamcinolone acetonide.
The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
